- Year-to-Date Revenue Grows 105% over Prior Year - CARLSBAD,
Calif., Nov. 7 /PRNewswire-FirstCall/ -- Alphatec Holdings, Inc.
(NASDAQ:ATEC), a spinal device company, today announced financial
results for the third quarter and nine months ended September 30,
2006. Revenue in the third quarter of 2006 increased 51% to $17.4
million compared with $11.5 million in the third quarter of 2005,
and represented an 11% decrease from the $19.4 million reported in
the second quarter of 2006. Gross profit for the third quarter of
2006 was $10.8 million with a gross margin of 61.9%, compared with
a gross profit of $6.5 million with a gross margin of 56.8% in the
third quarter of 2005. For the second quarter of 2006, gross profit
was $12.9 million with a gross margin of 66.2%. Total operating
expenses were $16.4 million in the third quarter of 2006, compared
to $11.0 million in the 2005 third quarter and $16.7 million in the
2006 second quarter. The increase from 2005 was principally due to
increases in the sales force, higher commissions due to the higher
volume, and expansion of R&D, engineering, and production. The
net loss for the third quarter of 2006 was $5.5 million, or $0.16
loss per share, compared to the $5.3 million, or $0.29 loss per
share, in the third quarter of 2005. Revenue for the nine months
ended September 30, 2006 increased by 105% to $54.8 million
compared to $26.7 million for the same period in 2005. Gross profit
for the nine months ended September 30, 2006 rose by 121% to $35.2
million with a gross margin of 64.3%, compared with a gross profit
of $16.0 million with a gross margin of 59.7% in the nine months
ended September 30, 2005. Net loss for the nine months ended
September 30, 2006 was $17.9 million, or $0.72 loss per share,
compared to a net loss of $13.2 million, or $0.73 loss per share,
for the nine months of 2005. "As evidenced by the 105% increase in
year-to-year revenue, our business is strong and growing," said
John H. Foster, Executive Chairman. "We understand there is much
work to be done in order to ensure long-term growth, and it was for
this reason that we initiated a sales force enhancement program
early in the third quarter. While some one-time organizational
instability related to this program impacted our third quarter
results, we are confident in our guidance for fourth quarter
revenue." Alphatec expects to achieve breakeven on cash flow from
operations at approximately $80 million in annual revenues, as
indicated by our second quarter EBITDA. The Company's EBITDA was
negative $2.5 million in the third quarter, as is projected to be
the case in the fourth quarter. Corporate cash flow was negative
$3.7 million in the third quarter, due to building inventory. In
the fourth quarter, corporate cash flow is anticipated to be
negative by about $4.5 million, due to approximately $1 million of
non- recurring Scient'X acquisition costs and inventory building.
The cash balance at September 30, 2006 was $21.4 million, a
decrease of $3.7 million from the June balance. At December 31,
2006, cash is expected to be approximately $17 million. Alphatec is
confident that this cash balance is sufficient to fund the 2007
business plan. "The acquisition of Scient'X is an excellent
strategic complement to Alphatec and, therefore, we are committed
to exploring all avenues in order to ensure a successful
transaction," said Mr. Foster. "However, we recognize that at our
current share price, it is not possible to close this transaction
pursuant to the existing terms of our agreement with Scient'X."
Non-GAAP Information Earnings before interest, taxes, depreciation,
and amortization ("EBITDA") included in this press release is a
non-GAAP (generally accepted accounting principles) financial
measure which represents net income (loss) excluding the effects of
interest, taxes, depreciation, amortization and stock based
compensation costs. EBITDA, as defined above, may not be similar to
EBITDA measures used by other companies and is not a measurement
under generally accepted accounting principles. The Company
believes that EBITDA provides useful information to investors about
the Company's performance because it eliminates the effects of
period to period changes in costs that are not directly
attributable to the underlying performance of the Company's
business operations. Management uses EBITDA in evaluating the
overall performance of the Company's business operations. Though
management finds EBITDA useful for evaluating aspects of the
Company's business, its reliance on this measure is limited because
excluded items often have a material effect on the Company's
earnings and earnings per common share calculated in accordance
with GAAP. Therefore, management always uses EBITDA in conjunction
with GAAP earnings and earnings per common share measures. The
Company believes that EBITDA provides investors with an additional
tool for evaluating the Company's core performance, which
management uses in its own evaluation of performance, and a
base-line for assessing the future earnings potential of the
Company. While the GAAP results are more complete, the Company
prefers to allow investors to have this supplemental metric since,
with a reconciliation to GAAP, it may provide greater insight into
the Company's financial results. Conference Call Alphatec will host
a conference call today at 5:00 p.m. ET / 2:00 p.m. PT to discuss
the results. A webcast of the conference call will be available on
the Internet live and for 12 months thereafter at the following
URL: http://www.videonewswire.com/event.asp?id=36425 About Alphatec
Alphatec is a medical device company focused on the design,
development, manufacturing and marketing of products for the
surgical treatment of spine disorders. Alphatec's principal product
offerings are primarily focused on the U.S. spine fusion market,
which is estimated to approach $3 billion in 2007, through its
wholly-owned subsidiary, Alphatec Spine, Inc., and include a
variety of spinal implant products and systems comprised of
components such as spine screws, spinal spacers, and plates that
offer multiple solutions to address patients' needs. In addition to
Alphatec's U.S. presence, it also participates in the Japanese
spine fusion and orthopedic trauma markets through its subsidiary,
Alphatec Pacific, Inc. Our mission is to be a values based leader
in the spinal device market by providing unmatched service to and
taking scientific direction from our surgeon customers. We do so
through our unique in-house manufacturing facility in Carlsbad,
California that allows us to respond quickly to surgeon needs and
to customize innovative products needed for spine fusion surgery.
Forward Looking Statements This press release may contain
forward-looking statements that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward- looking statements. Alphatec cautions investors that there
can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such
forward-looking statements as a result of various factors,
including, but not limited to, the following: Alphatec's ability to
maintain its level of previously reported sales growth, Alphatec's
ability to develop and expand its spine fusion business in the
United States and Japan, Alphatec's ability to enter into licensing
and business combination agreements with third parties and
successful integrate the acquired technology, Alphatec's ability to
expand and maintain a successful sales and marketing organization,
continuation of favorable third party payor reimbursement for
procedures performed using our products, unanticipated expenses or
liabilities or other adverse events affecting cash flow or
Alphatec's ability to achieve profitability, uncertainty of
additional funding, uncertainty of success in developing any new
products, failure to successfully introduce and develop new
products, including products related to license agreements, failure
to obtain FDA clearance or approval for particular devices,
Alphatec's ability to compete with other competing products and
with emerging new technologies within and outside of spinal fusion,
product liability exposure, patent infringement claims and claims
related to our intellectual property. Please refer to the risks
detailed in Alphatec's Form S-1 on file with the SEC, as well as
the risks detailed from time to time in Alphatec's SEC reports,
including quarterly reports on Form 10-Q, reports on Form 8-K and
annual reports on Form 10-K. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise, unless required by law. ALPHATEC HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in
thousands, except per share data) Three Months Ended Nine Months
Ended September 30, September 30, 2006 2005 2006 2005 Revenue
$17,358 $11,527 $54,809 $26,748 Cost of goods sold 6,606 4,984
19,583 10,790 Gross profit 10,752 6,543 35,226 15,958 % revenue
61.9% 56.8% 64.3% 59.7% Operating expenses: Research &
development 1,016 173 2,576 643 In-process research &
development 0 0 0 3,100 Sales & marketing 8,587 5,087 23,130
11,815 General and administrative 6,758 5,735 22,050 11,090 Total
operating expenses 16,361 10,995 47,756 26,648 Operating income
(loss) (5,609) (4,452) (12,530) (10,690) Interest and other income
(expense), net 171 (693) (2,026) (873) Income (loss) before taxes
(5,438) (5,145) (14,556) (11,563) Income taxes 0 (1,656) (64)
(2,113) Net income (loss) (5,438) (3,489) (14,492) (9,450)
Accretion to redemption value of redeemable convertible preferred
(30) (1,827) (3,480) (3,767) Net income (loss) applicable to common
stockholders $(5,468) $(5,316) $(17,972) $(13,217) Net income
(loss) per common share: Basic $(0.16) $(0.29) $(0.72) $(0.73)
Diluted $(0.16) $(0.29) $(0.72) $(0.73) Weighted-average shares:
Basic 33,370 18,587 25,105 18,008 Diluted 33,370 18,587 25,105
18,008 Non-GAAP information: EBITDA: Net income (loss) (5,438)
(3,489) (14,492) (9,450) Addback: Interest expense (261) 761 2,031
946 Stock based compensation 1,165 428 4,690 2,588 Income tax
provision (benefit) 0 (1,656) (64) (2,113) Depreciation 1,118 301
2,606 877 Amortization of intangibles 857 693 2,528 1,378 Total
EBITDA $(2,559) $(2,962) $(2,701) $(5,774) ALPHATEC HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)
September 30, December 31, 2006 2005 (unaudited) ASSETS Current
assets: Cash and cash equivalents $21,360 $2,180 Accounts
receivable, net 10,417 9,361 Inventories, net 12,370 8,458 Prepaid
expenses and other current assets 2,325 1,050 Deferred income taxes
- 3,057 Total current assets 46,472 24,106 Property and equipment,
net 11,774 7,206 Goodwill 60,509 60,946 Intangibles, net 11,102
13,644 Other assets 1,552 3,237 Total assets $131,409 $109,139
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts
payable $5,256 $4,103 Accrued expenses 8,635 8,736 Income taxes
payable 59 96 Lines of credit 1,696 3,942 Current portion of
long-term debt 2,333 2,980 Total current liabilities 17,979 19,857
Total long term liabilities 4,226 7,276 Minority Interest 3,288
1,914 Total equity 105,916 80,092 Total liabilities and
stockholders' equity $131,409 $109,139 Contacts: Alphatec Holdings,
Inc. Noonan Russo Steven Yasbek Brian Ritchie 760.431.9286 x503
212.845.4269 DATASOURCE: Alphatec Holdings, Inc. CONTACT: Steven
Yasbek, Alphatec Holdings, Inc., +1-760-431-9286 x 503, ; or Brian
Ritchie, Noonan Russo, +1-212-845-4269, Web site:
http://www.videonewswire.com/event.asp?id=36425
Copyright
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jul 2023 bis Jul 2024